The company has started enrolling patients into a run-in period for the Phase III study, and plans to begin dosing later this ...
ImmunityBio, Inc. (NASDAQ: IBRX) today announced an update on the status of enrollment in its randomized registrational trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback